TORONTO, Feb. 12 /CNW/ - Predictive medicine company PreMD Inc. (TSX:
PMD; Amex: PME) today provided an update on the company's business direction
in light of the recent decision from the U.S. Food and Drug Administration
Appeal to the FDA
PreMD today filed a request for a second level review of the 510(k)
submission, in accordance with the following Code of Federal Regulations 21
CFR part 10.75(c). As announced on Jan. 15, the company received a
non-substantially equivalent (NSE) letter from the FDA regarding the 510(k)
submission for an expanded regulatory claim on its point-of-care (POC) skin
cholesterol test. PreMD continues to believe that its skin cholesterol test
merits 510(k) clearance. "We have acted as quickly as possible in initiating
the process and will continue to evaluate the best strategies to help achieve
FDA clearance," said Brent Norton, president and chief executive officer of
PreMD. PreMD is working with AstraZeneca Pharmaceuticals, which has licensed
the test for marketing and distribution in the United States, to fully explore
the issues raised by the FDA and address the appropriate steps going forward.
Additional Company Information
In light of PreMD's financial status, the company also has taken actions
to maximize company value. These actions include a workforce reduction of
approximately 33% and other general and administrative expense decreases. The
key members of PreMD are concentrating their efforts on the FDA review and
assessing strategic alternatives to maximize shareholder value. PreMD will
continue to realign its organization and optimize the company's cost structure
and cash resources. PreMD continues to advance the development programs for
other product candidates in its oncology pipeline, which remain unaffected by
the FDA decision.
PreMD also recently appointed Ronald Henriksen as Chair of the Audit
Committee. Mr. Henriksen has been a director of PreMD since 2004 and is the
chief investment officer of Twilight Ventures.
About PreMD Inc.
PreMD Inc. is a leader in predictive medicine, dedicated to developing
rapid, non-invasive tests for the early detection of life-threatening
diseases. PreMD's cardiovascular products include a line of non-invasive skin
cholesterol tests. PreMD's other skin cholesterol products include PREVU(*) LT,
a test designed for use in the life insurance industry. The company's cancer
tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test.
PreMD's head office is located in Toronto, Ontario and its research and
product development facility is at McMaster University in Hamilton, Ontario.
For more information about PreMD, please visit www.premdinc.com.
This press release contains forward-looking statements. These statements
involve known and unknown risks and uncertainties, which could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include, among
others, the successful development or marketing of the Company's products, the
competitiveness of the Company's products if successfully commercialized, the
lack of operating profit and availability of funds and resources to pursue R&D
projects, the successful and timely completion of clinical studies, product
liability, reliance on third-party manufacturers, the ability of the Company
to take advantage of business opportunities, uncertainties related to the
regulatory process, and general changes in economic conditions. In addition,
while the Company routinely obtains patents for its products and technology,
the protection offered by the Company's patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there can be no
guarantee of our ability to obtain or maintain patent protection for our
products or product candidates.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors
are cautioned not to rely on these forward-looking statements. PreMD is
providing this information as of the date of this press release and does not
undertake any obligation to update any forward-looking statements contained in
this press release as a result of new information, future events or otherwise.
%SEDAR: 00007927E %CIK: 0001179083
For further information:
For further information: Ron Hosking, Vice-President Finance and CFO,
Tel: (416) 222-3449 ext. 24, Email: firstname.lastname@example.org; Michelle Rabba,
Manager, Corporate Communications, Tel: (416) 222-3449 ext 25, Email: